Table 2.
Adverse events with concurrent chemoradiotherapy.
| Characteristic | Experimental group (n = 50) | Control group (n = 54) | p |
|---|---|---|---|
| Myelosuppression | |||
| Grade 1–2 | 26 | 25 | 0.695 |
| Grade 3 | 24 | 37 | 0.034 |
| Grade 4 | 4 | 3 | 0.708 |
| Leukopenia | 0.10 | ||
| Grade 0 | 7 | 1 | |
| Grade 1 | 5 | 5 | |
| Grade 2 | 20 | 21 | |
| Grade 3 | 18 | 27 | |
| Grade 4 | 0 | 0 | |
| Neutropenia | 0.83 | ||
| Grade 0 | 9 | 10 | |
| Grade 1 | 14 | 17 | |
| Grade 2 | 15 | 18 | |
| Grade 3 | 12 | 9 | |
| Grade 4 | 0 | 0 | |
| Anemia | 0.32 | ||
| Grade 0 | 12 | 6 | |
| Grade 1 | 16 | 16 | |
| Grade 2 | 17 | 22 | |
| Grade 3 | 3 | 8 | |
| Grade 4 | 2 | 2 | |
| Thrombocytopenia | 0.53 | ||
| Grade 0 | 25 | 26 | |
| Grade 1 | 11 | 19 | |
| Grade 2 | 9 | 6 | |
| Grade 3 | 3 | 2 | |
| Grade 4 | 2 | 1 | |
| Liver damage | 0.15 | ||
| Grade 0 | 26 | 37 | |
| Grade 1 | 16 | 14 | |
| Grade 2 | 7 | 2 | |
| Grade 3 | 1 | 1 | |
| Grade 4 | 0 | 0 | |
| Bilirubin | 0.83 | ||
| Grade 0 | 47 | 51 | |
| Grade 1 | 3 | 2 | |
| Grade 2 | 0 | 0 | |
| Grade 3 | 0 | 0 | |
| Grade 4 | 0 | 1 | |
| Increased alanine aminotransferase | 0.26 | ||
| Grade 0 | 39 | 47 | |
| Grade 1 | 4 | 4 | |
| Grade 2 | 6 | 2 | |
| Grade 3 | 0 | 1 | |
| Grade 4 | 1 | 0 | |
| Increased alkaline phosphatase | 0.26 | ||
| Grade 0 | 29 | 37 | |
| Grade 1 | 17 | 15 | |
| Grade 2 | 4 | 1 | |
| Grade 3 | 0 | 0 | |
| Grade 4 | 0 | 1 | |
| Creatinine increased | |||
| Grade 0–4 | 0 | 0 | |
| Urea nitrogen increased | |||
| Grade 0–4 | 0 | 0 | |
| Proteinuria | |||
| Grade 0–4 | 0 | 0 | |
| Diarrhea | 5 | 4 | 0.735 |